Enhancing organoid technology with carbon-based nanomaterial biosensors: Advancements, challenges, and future directions

  • Zahra Rezaei
  • , Niyou Wang
  • , Yipei Yang
  • , Kannan Govindaraj
  • , Jose Joaquin Velasco
  • , Alvaro Dario Martinez Blanco
  • , Nam Ho Bae
  • , Hea Yeon Lee
  • , Su Ryon Shin*
  • *Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

12 Citations (Scopus)
1 Downloads (Pure)

Abstract

Various carbon-based nanomaterials (CBNs) have been utilized to develop nano- and microscale biosensors that enable real-time and continuous monitoring of biochemical and biophysical changes in living biological systems. The integration of CBN-based biosensors into organoids has recently provided valuable insights into organoid development, disease modeling, and drug responses, enhancing their functionality and expanding their applications in diverse biomedical fields. These biosensors have been particularly transformative in studying neurological disorders, cardiovascular diseases, cancer progression, and liver toxicity, where precise, non-invasive monitoring is crucial for understanding pathophysiological mechanisms and assessing therapeutic efficacy. This review introduces intra- and extracellular biosensors incorporating CBNs such as graphene, carbon nanotubes (CNTs), graphene oxide (GO), reduced graphene oxide (rGO), carbon dots (CDs), and fullerenes. Additionally, it discusses strategies for improving the biocompatibility of CBN-based biosensors and minimizing their potential toxicity to ensure long-term organoid viability. Key challenges such as biosensor integration, data accuracy, and functional compatibility with specific organoid models are also addressed. Furthermore, this review highlights how CBN-based biosensors enhance the precision and relevance of organoid models in biomedical research, particularly in organ-specific applications such as brain-on-a-chip systems for neurodegenerative disease studies, liver-on-a-chip platforms for hepatotoxicity screening, and cardiac organoids for assessing cardiotoxicity in drug development. Finally, it explores how biosensing technologies could revolutionize personalized medicine by enabling high throughput drug screening, patient-specific disease modeling, and integrated sensing platforms for early diagnostics. By capturing current advancements and future directions, this review underscores the transformative potential of carbon-based nanotechnology in organoid research and its broader impact on medical science.

Original languageEnglish
Article number115592
Number of pages17
JournalAdvanced drug delivery reviews
Volume222
Early online date3 May 2025
DOIs
Publication statusPublished - Jul 2025

Keywords

  • 2025 OA procedure
  • Nano-biosensors
  • Organoids
  • Personalized medicine
  • Real-time monitoring
  • Therapeutic modeling
  • Carbon-based nanomaterials

Fingerprint

Dive into the research topics of 'Enhancing organoid technology with carbon-based nanomaterial biosensors: Advancements, challenges, and future directions'. Together they form a unique fingerprint.

Cite this